News for Healthier Living

Novel Antibody-Drug Conjugate Eliminates Residual Cancer Cells in Majority of Patients with B-Cell ALL

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.

July 7, 2026


July 21 2026

July 20 2026

July 17 2026

July 16 2026

July 15 2026

July 14 2026

July 13 2026

July 12 2026

July 10 2026

July 9 2026

July 8 2026

July 7 2026